2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | (単位:百万円) |
| 前連結会計年度 (2025年12月31日) | 当第3四半期連結会計期間 (2026年9月30日) |
資産 | | |
流動資産 | | |
現金及び現金同等物 | 1,387 | 1,023 |
営業債権及びその他の債権 | 374 | 116 |
棚卸資産 | 112 | 104 |
その他の流動資産 | 15 | 49 |
流動資産合計 | 1,890 | 1,294 |
非流動資産 | | |
有形固定資産 | 16 | 15 |
使用権資産 | 97 | 71 |
その他の金融資産 | 141 | 179 |
非流動資産合計 | 254 | 266 |
資産合計 | 2,145 | 1,560 |
| | |
負債及び資本 | | |
負債 | | |
流動負債 | | |
営業債務及びその他の債務 | 229 | 78 |
リース負債 | 31 | 31 |
その他の流動負債 | 51 | 48 |
流動負債合計 | 312 | 159 |
非流動負債 | | |
繰延税金負債 | 5 | 6 |
リース負債 | 64 | 38 |
その他の非流動負債 | 11 | 10 |
非流動負債合計 | 80 | 55 |
負債合計 | 393 | 215 |
資本 | | |
資本金 | 836 | 967 |
資本剰余金 | 1,455 | 1,584 |
利益剰余金 | △521 | △1,202 |
自己株式 | △65 | △65 |
その他の資本の構成要素 | 47 | 60 |
資本合計 | 1,752 | 1,345 |
負債及び資本合計 | 2,145 | 1,560 |
E3304445970ソレイジア・ファーマ株式会社Solasia Pharma K.K.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2026-01-012026-09-30Q32026-12-312025-01-012025-09-302025-12-311falsefalsefalse459702025-01-012025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-09-30jpigp_cor:ShareCapitalIFRSMember459702025-09-30jpigp_cor:CapitalSurplusIFRSMember459702025-09-30jpigp_cor:RetainedEarningsIFRSMember459702025-09-30jpigp_cor:TreasurySharesIFRSMember459702025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702026-01-012026-09-30jpigp_cor:ShareCapitalIFRSMember459702026-01-012026-09-30jpigp_cor:CapitalSurplusIFRSMember459702026-01-012026-09-30jpigp_cor:RetainedEarningsIFRSMember459702026-01-012026-09-30jpigp_cor:TreasurySharesIFRSMember459702026-01-012026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember459702026-01-012026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702026-09-30jpigp_cor:ShareCapitalIFRSMember459702026-09-30jpigp_cor:CapitalSurplusIFRSMember459702026-09-30jpigp_cor:RetainedEarningsIFRSMember459702026-09-30jpigp_cor:TreasurySharesIFRSMember459702026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember459702026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702026-01-012026-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702026-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-01-012025-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-09-30jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-12-31459702025-12-31459702025-01-012025-09-30459702025-09-30459702026-01-012026-09-30459702026-09-30459702026-11-12459702024-12-31jpigp_cor:ShareCapitalIFRSMember459702024-12-31jpigp_cor:CapitalSurplusIFRSMember459702024-12-31jpigp_cor:RetainedEarningsIFRSMember459702024-12-31jpigp_cor:TreasurySharesIFRSMember459702024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-12-31jpigp_cor:ShareCapitalIFRSMember459702025-12-31jpigp_cor:CapitalSurplusIFRSMember459702025-12-31jpigp_cor:RetainedEarningsIFRSMember459702025-12-31jpigp_cor:TreasurySharesIFRSMember459702025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-01-012025-09-30jpigp_cor:ShareCapitalIFRSMember459702025-01-012025-09-30jpigp_cor:CapitalSurplusIFRSMember459702025-01-012025-09-30jpigp_cor:RetainedEarningsIFRSMember459702025-01-012025-09-30jpigp_cor:TreasurySharesIFRSMember459702025-01-012025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure